Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Enveric Biosciences Inc
(NQ:
ENVB
)
0.4330
-0.0410 (-8.65%)
Streaming Delayed Price
Updated: 3:58 PM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
164,028
Open
0.4750
Bid (Size)
0.4330 (7)
Ask (Size)
0.4727 (6)
Prev. Close
0.4740
Today's Range
0.4200 - 0.4750
52wk Range
0.4100 - 2.920
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop
September 26, 2024
From
Enveric Biosciences
Via
Business Wire
Non-Hallucinogenic Psychedelic Treatment For Anxiety And Depression In Pre-Clinical Models: Enveric Biosciences' Breakthrough Research
September 25, 2024
Psychedelics biotech company Enveric Biosciences (NASDAQ: ENVB) has presented research highlighting the company's lead compound, EB-003 at the 7th Neuropsychiatric Drug Summit. The conference is being...
Via
Benzinga
Performance
YTD
-65.63%
-65.63%
1 Month
-15.11%
-15.11%
3 Month
-25.78%
-25.78%
6 Month
-51.35%
-51.35%
1 Year
-80.76%
-80.76%
More News
Read More
Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit
September 25, 2024
From
Enveric Biosciences
Via
Business Wire
Why Is Enveric Biosciences (ENVB) Stock Up 18% Today?
July 30, 2024
Via
InvestorPlace
Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024
From
Enveric Biosciences
Via
Business Wire
Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries’ License for Treatment of Radiation Dermatitis and Other Conditions
August 13, 2024
From
Enveric Biosciences
Via
Business Wire
ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q2 2024
August 12, 2024
Via
InvestorPlace
Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results
August 12, 2024
From
Enveric Biosciences
Via
Business Wire
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
July 30, 2024
Via
Benzinga
Why Is Imunon (IMNN) Stock Up 259% Today?
July 30, 2024
Via
InvestorPlace
Why Is Ekso Bionics (EKSO) Stock Down 15% Today?
July 30, 2024
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
July 30, 2024
Via
InvestorPlace
Why F5 Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
July 30, 2024
Via
Benzinga
Non-Hallucinogenic Psychedelic Treatment For Mental Health Disorders Shows Potential To Be Dosed Orally
July 25, 2024
Via
Benzinga
Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally
July 25, 2024
From
Enveric Biosciences
Via
Business Wire
Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement
July 15, 2024
From
Enveric Biosciences
Via
Business Wire
New Patented Psychedelic Drug Brings Hope For Brain Disorder Therapies
July 11, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Enveric Biosciences Announces Patent Granted for Drug Candidate
July 10, 2024
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate
June 25, 2024
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences to Participate in BIO International Convention 2024
May 30, 2024
From
Enveric Biosciences
Via
Business Wire
ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q1 2024
May 20, 2024
Via
InvestorPlace
'Psychedelics-Inspired' Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand
May 16, 2024
Via
Benzinga
Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results
May 15, 2024
From
Enveric Biosciences
Via
Business Wire
Microdosing For Depression: Psychedelics Biotech Signs $66.5M Non-Binding Deal To Out-License Novel Psilocin Prodrug Candidate
May 14, 2024
Via
Benzinga
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
May 14, 2024
From
Enveric Biosciences
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.